Eli Lilly made a $32 billion investment push by acquiring 13 biotech companies

The year 2026 has become a defining moment for the biotechnology industry, not only because of new drug discoveries but also because of an unprecedented wave of large-scale acquisitions. At the center of this activity is Eli Lilly, which announced its 13th acquisition of the year by agreeing to acquire Merida Biosciences in a deal worth up to $2.875 billion. With this transaction, Lilly's total acquisition spending in 2026 has reached approximately $32 billion.

This strategy demonstrates that Lilly's growth ambitions extend far beyond weight-loss medicines. After gaining significant momentum through its GLP-1 portfolio over the past few years, the company is now deploying that financial strength toward long-term growth areas including autoimmune diseases, allergy therapeutics, and oncology. It represents one of the clearest examples of how major pharmaceutical companies are increasingly investing in external innovation alongside internal R&D.

Why immunology has become the acquisition focus

The most prominent asset in Merida Biosciences' portfolio is MER511, an experimental therapy currently in Phase 1 development. The candidate is designed to treat Graves' disease, an autoimmune disorder in which the immune system attacks the thyroid gland, as well as thyroid eye disease, a serious complication associated with the condition. Early clinical data suggest meaningful reductions in disease-causing antibody levels alongside a promising initial safety profile. With approximately 3 million people in the United States living with Graves' disease and a substantial proportion developing thyroid eye disease, the commercial opportunity is significant.

Merida's pipeline extends beyond a single asset. The company is also developing MER769 for immune-mediated conditions including food allergies, asthma, and chronic spontaneous urticaria. This broader portfolio reflects Lilly's strategy of building a diversified immunology ecosystem rather than relying on a single therapeutic area.

Lilly's recently released clinical data further reinforce this approach. Phase 3b studies evaluating the combination of Taltz and Zepbound in patients with psoriasis produced notable results. After 52 weeks, 30.6% of patients receiving the combination therapy achieved both completely clear skin and at least a 10% reduction in body weight, compared with only 4.4% of patients treated with Taltz alone.

Big Pharma's new growth model

These findings suggest that addressing obesity and inflammatory diseases together could reshape future treatment strategies. Similar benefits were observed in patients with psoriatic arthritis, where the combination therapy delivered significantly stronger outcomes than single-agent treatments. The results further strengthen Lilly's platform strategy of connecting multiple therapeutic areas rather than developing them in isolation.

The company's acquisition spree also sends an important signal to the biotechnology investment ecosystem. With roughly $32 billion committed across multiple deals, Lilly is creating new exit opportunities for startup investors while demonstrating that large pharmaceutical companies are becoming increasingly aggressive in pursuing early-stage biotechnology firms. In today's market, success is no longer defined solely by discovering a new molecule; becoming an attractive strategic acquisition target has emerged as an equally important growth pathway.

From a broader perspective, these developments point toward a new phase for the biotechnology industry. Alongside lengthy internal R&D programs, major pharmaceutical companies are increasingly choosing to accelerate portfolio expansion by acquiring innovative early-stage platforms. Eli Lilly's actions throughout 2026 suggest that the next chapter of competition in biotech will be shaped not only inside laboratories, but also around strategic acquisition tables.